Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication August 31, 2012
- Accepted for publication April 23, 2013
- Published online October 1, 2013.
Article Versions
- previous version (August 22, 2013 - 05:20).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2013 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Mary L. Gemignani1,
- Sujata Patil2,
- Venkatraman E. Seshan2,
- Michelle Sampson1,
- John L. Humm3,
- Jason S. Lewis4,
- Edi Brogi5,
- Steven M. Larson4,
- Monica Morrow1 and
- Neeta Pandit-Taskar4
- 1Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York
- 2Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York
- 3Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York
- 4Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York; and
- 5Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York
- For correspondence contact: Mary L. Gemignani, Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 300 E. 66th St. New York, NY 10065. E-mail: gemignam{at}mskcc.org
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes
- 18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT
- Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial
- 18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
- Functional Estrogen Receptor Imaging Before Neoadjuvant Therapy for Primary Breast Cancer
- A Randomized Feasibility Study of 18F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer
- Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer
- 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications
- Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation